Enzymatic properties of the neuraminidase of seasonal H1N1 influenza viruses provide insights for the emergence of natural resistance to oseltamivir

PLoS Pathogens

Volumn 4, Issue 7, 2008, Pages

  Rameix Welti, Marie Anne ^a   Enouf, Vincent ^b   Cuvelier, Frédérique ^b   Jeannin, Patricia ^b   Van Der Werf, Sylvie ^a,b  

^a CNRS   (France)

^b INSTITUT PASTEUR   (France)

Author keywords

[No Author keywords available]

Indexed keywords

OSELTAMIVIR; SIALIDASE; ZANAMIVIR; ANTIVIRUS AGENT; CYTOKINE; ENZYME INHIBITOR; SCGB3A1 PROTEIN, HUMAN; TUMOR SUPPRESSOR PROTEIN; VIRUS DNA;

ENZYME ACTIVITY; ENZYME ANALYSIS; HUMAN; INFLUENZA VIRUS A H1N1; NONHUMAN; NOTE; NUCLEOTIDE SEQUENCE; VIRUS RESISTANCE; ANTIVIRAL RESISTANCE; ARTICLE; DRUG ANTAGONISM; DRUG EFFECT; ENZYMOLOGY; MICROBIOLOGICAL EXAMINATION; MOLECULAR GENETICS; PHYLOGENY; PHYSIOLOGY; SEASON; VIRUS REPLICATION;

ORTHOMYXOVIRIDAE;

ANTIVIRAL AGENTS; BASE SEQUENCE; CYTOKINES; DNA, VIRAL; DRUG RESISTANCE, VIRAL; ENZYME INHIBITORS; INFLUENZA A VIRUS, H1N1 SUBTYPE; MICROBIAL SENSITIVITY TESTS; MOLECULAR SEQUENCE DATA; NEURAMINIDASE; OSELTAMIVIR; PHYLOGENY; SEASONS; TUMOR SUPPRESSOR PROTEINS; VIRUS REPLICATION;

EID: 48249156625     PISSN: 15537366     EISSN: 15537374     Source Type: Journal    
DOI: 10.1371/journal.ppat.1000103     Document Type: Note

References (33)

1. Lackenby A, Hungnes O, Dudman SG, Meijer A, Paget WJ, et al. (2008) Emergence of resistance to oseltamivir among influenza A(H1N1) viruses in Europe. Euro Surveill 13: 31 January 2008. Available: http://www. eurosurveillance.org/ViewArticle.aspx?ArticleId=8026. Accessed 27 June 2008.
2. World Health Organization (2008) Influenza A(H1N1) virus resistance to oseltamivir. Available: http://www.who.int/csr/disease/influenza/h1n1_table/en/ index.html. Accessed 26 June 2008.
3. European Centre for Disease Prevention and Control (2008) Oseltamivir resistance in human seasonal influenza type A/H1N1 isolates in Europe. Available: http://ecdc.europa.eu/Health_topics/influenza/antivirals_graph.html. Accessed 26 June 2008.
4. Escuret V, Frobert E, Bouscambert-Duchamp M, Sabatier M, Grog I, et al. (2008) Detection of human influenza A (H1N1) and B strains with reduced sensitivity to neuraminidase inhibitors. J Clin Virol 41: 25-28.
5. Hurt AC, McKimm-Breschkin JL, McDonald M, Barr IG, Komadina N, et al. (2004) Identification of a human influenza type B strain with reduced sensitivity to neuraminidase inhibitor drugs. Virus Res 103: 205-211.
6. McKimm-Breschkin J, Trivedi T, Hampson A, Hay A, Klimov A, et al. (2003) Neuraminidase sequence analysis and susceptibilities of influenza virus clinical isolates to zanamivir and oseltamivir. Antimicrob Agents Chemother 47: 2264-2272.
7. Monto AS, McKimm-Breschkin JL, Macken C, Hampson AW, Hay A, et al. (2006) Detection of influenza viruses resistant to neuraminidase inhibitors in global surveillance during the first 3 years of their use. Antimicrob Agents Chemother 50: 2395-2402.
8. Mungall BA, Xu X, Klimov A (2004) Surveillance of influenza isolates for susceptibility to neuraminidase inhibitors during the 2000-2002 influenza seasons. Virus Res 103: 195-197.
9. Abed Y, Goyette N, Boivin G (2004) A reverse genetics study of resistance to neuraminidase inhibitors in an influenza A/H1N1 virus. Antivir Ther 9: 577-581.
10. Gubareva LV, Kaiser L, Matrosovich MN, Soo-Hoo Y, Hayden FG (2001) Selection of influenza virus mutants in experimentally infected volunteers treated with oseltamivir. J Infect Dis 183: 523-531.
11. Wang MZ, Tai CY, Mendel DB (2002) Mechanism by which mutations at his274 alter sensitivity of influenza a virus n1 neuraminidase to oseltamivir carboxylate and zanamivir. Antimicrob Agents Chemother 46: 3809-3816.
12. Wetherall NT, Trivedi T, Zeller J, Hodges-Savola C, McKimm-Breschkin JL, et al. (2003) Evaluation of neuraminidase enzyme assays using different substrates to measure susceptibility of influenza virus clinical isolates to neuraminidase inhibitors: report of the neuraminidase inhibitor susceptibility network. J Clin Microbiol 41: 742-750.
13. Ward P, Small I, Smith J, Suter P, Dutkowski R (2005) Oseltamivir (Tamiflu) and its potential for use in the event of an influenza pandemic. J Antimicrob Chemother 55 Suppl 1: i5-i21.
14. Herlocher ML, Truscon R, Elias S, Yen HL, Roberts NA, et al. (2004) Influenza viruses resistant to the antiviral drug oseltamivir: transmission studies in ferrets. J Infect Dis 190: 1627-1630.
15. Ives JA, Carr JA, Mendel DB, Tai CY, Lambkin R, et al. (2002) The H274Y mutation in the influenza A/H1N1 neuraminidase active site following oseltamivir phosphate treatment leave virus severely compromised both in vitro and in vivo. Antiviral Res 55: 307-317.
16. Abed Y, Baz M, Boivin G (2006) Impact of neuraminidase mutations conferring influenza resistance to neuraminidase inhibitors in the N1 and N2 genetic backgrounds. Antivir Ther 11: 971-976.
17. Le QM, Kiso M, Someya K, Sakai YT, Nguyen TH, et al. (2005) Avian flu: isolation of drug-resistant H5N1 virus. Nature 437: 1108.
18. Yen HL, Ilyushina NA, Salomon R, Hoffmann E, Webster RG, et al. (2007) Neuraminidase inhibitor-resistant recombinant A/Vietnam/1203/04 (H5N1) influenza viruses retain their replication efficiency and pathogenicity in vitro and in vivo. J Virol 81: 12418-12426.
19. Mishin VP, Hayden FG, Gubareva LV (2005) Susceptibilities of antiviral-resistant influenza viruses to novel neuraminidase inhibitors. Antimicrob Agents Chemother 49: 4515-4520.
20. Rameix-Welti MA, Agou F, Buchy P, Mardy S, Aubin JT, et al. (2006) Natural variation can significantly alter sensitivity to oseltamivir of Influenza A(H5N1) viruses. Antimicrob Agents Chemother 50: 3809-3815.
21. Russell RJ, Haire LF, Stevens DJ, Collins PJ, Lin YP, et al. (2006) The structure of H5N1 avian influenza neuraminidase suggests new opportunities for drug design. Nature 443: 45-49.
22. Macken C, Lu H, Goodman J, Boykin L (2001) The value of a database in surveillance and vaccine selection. In: Osterhaus ADME, Cox N, Hampson AW, eds. Options for the control of influenza IV. Amsterdam: Elsevier Science. pp 103-106.
23. Wagner R, Matrosovich M, Klenk HD (2002) Functional balance between haemagglutinin and neuraminidase in influenza virus infections. Rev Med Virol 12: 159-166.
24. Bright RA, Medina MJ, Xu X, Perez-Oronoz G, Wallis TR, et al. (2005) Incidence of adamantane resistance among influenza A (H3N2) viruses isolated worldwide from 1994 to 2005: a cause for concern. Lancet 366: 1175-1181.
25. Bright RA, Shay DK, Shu B, Cox NJ, Klimov AI (2006) Adamantane resistance among influenza A viruses isolated early during the 2005-2006 influenza season in the United States. JAMA 295: 891-894.
26. Deyde VM, Xu X, Bright RA, Shaw M, Smith CB, et al. (2007) Surveillance of resistance to adamantanes among influenza A(H3N2) and A(H1N1) viruses isolated worldwide. J Infect Dis 196: 249-257.
27. Regoes RR, Bonhoeffer S (2006) Emergence of drug-resistant influenza virus: population dynamical considerations. Science 312: 389-391.
28. Simonsen L, Viboud C, Grenfell BT, Dushoff J, Jennings L, et al. (2007) The genesis and spread of reassortment human influenza A/H3N2 viruses conferring adamantane resistance. Mol Biol Evol 24: 1811-1820.
29. McKimm-Breschkin JL, Selleck PW, Usman TB, Johnson MA (2007) Reduced sensitivity of influenza A (H5N1) to oseltamivir. Emerg Infect Dis 13: 1354-1357.
30. Potier M, Mameli L, Belisle M, Dallaire L, Melancon SB (1979) Fluorometric assay of neuraminidase with a sodium (4-methylumbelliferyl-alpha-D- N-acetylneuraminate) substrate. Anal Biochem 94: 287-296.
31. Matrosovich M, Matrosovich T, Carr J, Roberts NA, Klenk HD (2003) Overexpression of the alpha-2,6-sialyltransferase in MDCK cells increases influenza virus sensitivity to neuraminidase inhibitors. J Virol 77: 8418-8425.
32. Felsenstein J (1989) PHYLIP-Phylogeny Inference Package (version 3.2). Cladistics 5: 164-166.
33. Felsenstein J (1993) PHYLIP (Phylogeny Inference Package) version 3.5c. Distributed by the author. Seattle: Department of Genetics, University of Washington.